TY - JOUR
T1 - Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
AU - Johannson, Kerri A
AU - Strâmbu, Irina
AU - Ravaglia, Claudia
AU - Grutters, Jan C
AU - Valenzuela, Claudia
AU - Mogulkoc, Nesrin
AU - Luppi, Fabrizio
AU - Richeldi, Luca
AU - Wells, Athol U
AU - Vancheri, Carlo
AU - Kreuter, Michael
AU - Albera, Carlo
AU - Antoniou, Katerina M.
AU - Altinisik, Goksel
AU - Bendstrup, Elisabeth
AU - Bondue, Benjamin
AU - Borie, Raphael
AU - Brown, Kevin K.
AU - Camus, Philippe
AU - Castillo, Diego
AU - Collard, Harold R.
AU - Cottin, Vincent
AU - Crimi, Nunzio
AU - Ferrara, Giovanni
AU - Fischer, Aryeh
AU - Gauldie, Jack
AU - Geiser, Thomas
AU - Guenther, Andreas
AU - Hambly, Nathan
AU - Hansell, David M.
AU - Harari, Sergio
AU - Jones, Mark G.
AU - Keane, Michael
AU - Ley, Brett
AU - Maher, Toby M.
AU - Molina-Molina, Maria
AU - Palmucci, Stefano
AU - Poletti, Venerino
AU - Prasse, Antje
AU - Rottoli, Paola
AU - Spagnolo, Paolo
AU - Sterclova, Martina
AU - Torrisi, Sebastiano
AU - Tsitoura, Eliza
AU - Vasakova, Martina
AU - Walsh, Simon L.
AU - Wijsenbeek, Marlies S.
AU - Wuyts, Wim A.
PY - 2017
Y1 - 2017
N2 - Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
AB - Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
KW - Antacids
KW - Disease Progression
KW - Gastroesophageal Reflux
KW - Histamine H2 Antagonists
KW - Humans
KW - Idiopathic Pulmonary Fibrosis
KW - Practice Guidelines as Topic
KW - Proton Pump Inhibitors
KW - Pulmonary and Respiratory Medicine
KW - Risk Factors
KW - Severity of Illness Index
KW - Antacids
KW - Disease Progression
KW - Gastroesophageal Reflux
KW - Histamine H2 Antagonists
KW - Humans
KW - Idiopathic Pulmonary Fibrosis
KW - Practice Guidelines as Topic
KW - Proton Pump Inhibitors
KW - Pulmonary and Respiratory Medicine
KW - Risk Factors
KW - Severity of Illness Index
UR - http://hdl.handle.net/10807/123033
UR - http://www.elsevier.com/journals/the-lancet-respiratory-medicine/2213-2600
U2 - 10.1016/S2213-2600(17)30219-9
DO - 10.1016/S2213-2600(17)30219-9
M3 - Article
SN - 2213-2600
VL - 5
SP - 591
EP - 598
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
ER -